Hydrogen-rich water is sold as an antioxidant shortcut: fizz a tablet, drink up, and calm the cellular fire. A new randomized, blinded, placebo-controlled trial in people living at high altitude found something awkward for that story. Over eight weeks, the hydrogen group's levels of malondialdehyde (MDA), a marker of oxidative damage, rose more than the placebo group's.
Before anyone pours their hydrogen water down the drain, the context matters. This was a small trial in a very specific population. But the result is a useful reality check for a product category that often runs ahead of its evidence.
What the researchers actually tested
The study, led by Zhang and colleagues and published in High Altitude Medicine & Biology (2026;27(3):133-142), asked a simple question: can hydrogen-rich water (HRW) reduce oxidative stress in people with chronic mountain sickness (CMS)?
CMS is a condition of long-term high-altitude residents. Oxidative stress is thought to contribute to it, which gave the team a rationale for testing an antioxidant approach.
The design:
- Setting: Tibetan Hospital of Nagqu, China, from July to December 2024
- Participants: Adults with untreated CMS (defined by the Qinghai score); 60 were randomized and 59 were analyzed, because one placebo participant never received treatment
- Intervention: 990 mL per day of HRW versus placebo for 8 weeks
- Allocation: 1:1 using a dynamic minimization method
- Blinding: Participants, clinicians and investigators
- Registration: ChiCTR2400082685
The primary endpoint was the change from baseline to week 8 in a panel of oxidative stress biomarkers: catalase, glutathione, MDA, superoxide dismutase, 8-hydroxy-2'-deoxyguanosine and total antioxidant capacity (T-AOC).
The twist: MDA went up, not down
At week 8, HRW produced greater changes than placebo in two markers:
- MDA: +2.11 (95% CI 1.13 to 3.09; p < 0.001)
- T-AOC: +2.86 (95% CI 0.09 to 5.64; p = 0.043)
MDA is widely used as a marker of lipid peroxidation, a form of oxidative damage, so a rise relative to placebo is the opposite of what an antioxidant therapy is supposed to deliver. T-AOC, a broader measure of antioxidant capacity, also rose.
The authors concluded that HRW showed both pro-oxidative and antioxidative effects in CMS. They also concluded that it did not reduce oxidative stress-induced damage.
The mixed signal is part of the story. Antioxidant capacity and a damage marker moved up together, so the picture is more complicated than "hydrogen water causes damage." The trial does not explain the mechanism.
Higher BMI, bigger signal
The subgroup finding is the most pointed one. In participants with a body mass index of 24 or higher, the MDA increase was more pronounced (Δ +2.57; p = 0.02 for interaction). The authors say HRW may increase oxidative risk in people with higher BMI.
This is a subgroup analysis in a small sample, so treat it as a flag for future research, not a settled rule. It does suggest that one-size-fits-all claims for hydrogen water deserve skepticism.
Safety: more adverse events, mostly dizziness
Adverse events occurred in 50% (15 of 30) of the hydrogen group and 37% (11 of 29) of the placebo group. Dizziness was the most common. The abstract doesn't break these down further, so it's hard to say how serious they were or whether the gap is meaningful with groups this small.
What this study can't tell you
This is where honesty matters, because the headline is easy to overgeneralize.
- Specific population: All participants had chronic mountain sickness and lived at altitude. Healthy sea-level adults may respond differently.
- Small sample: 59 analyzed participants is modest, and subgroup results are especially fragile.
- Surrogate markers: The outcomes were blood biomarkers of oxidative stress, not symptoms or clinical outcomes. A change in MDA doesn't prove a change in health.
- One regimen: The trial tested a single volume (990 mL/day) over eight weeks. It can't speak to other doses, products or hydrogen concentrations.
- No sign of bias from funding: The authors declared no competing interests, which is reassuring, but it doesn't remove the design limits above.
Practical takeaways
What the trial used: 990 mL per day of hydrogen-rich water for 8 weeks. The abstract gives no information on optimal timing, and no benefit was shown at this dose, so there is no evidence-based schedule to recommend.
Who this finding is most relevant to:
- People with chronic mountain sickness, or those considering HRW as an antioxidant treatment at altitude
- People with a BMI of 24 or higher who are using hydrogen water specifically to cut oxidative stress
Who should be cautious or skip it for now:
- Anyone with CMS: talk to a clinician instead of self-treating with hydrogen water
- Higher-BMI users hoping for antioxidant protection, given the stronger MDA rise in that subgroup
- People prone to dizziness, the most common adverse event reported
The bottom line: In this trial, hydrogen water did not lower oxidative damage and in fact raised MDA relative to placebo. That doesn't prove it's harmful for everyone, but it undercuts the assumption that more hydrogen means less oxidative stress. Larger trials in other populations, with clinical outcomes and a mechanistic explanation, are needed before the hype is justified.
